Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS), peripheral nervous system (PNS), and pain. Their team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization.
Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The company is listed on the SIX Swiss Exchange under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange, and on XETRA, trading symbol NP5.